FDA Grants Accelerated Approval to Dordaviprone for Diffuse Midline Glioma By Ogkologos - August 22, 2025 522 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on results from the ONC006, ONC013, ONC014, ONC016 and ONC018 studies Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Sevabertinib Shows Antitumour Activity in Patients with Locally Advanced or Metastatic... November 14, 2025 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... May 10, 2021 Patient Guide in Prostate Cancer Now Available Also in German December 18, 2025 Cancer Prevention and Screening Account for Most Cancer Deaths Averted Among... February 3, 2025 Load more HOT NEWS Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow Suggesting a Deadline in the Invitation Letter to FIT Colorectal Cancer... Investing in volunteers since 2002: The tale of time Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with...
